NASDAQ:LXEO | Free Cash Flow | Lexeo Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$21.14M$35,000.00-$21.18M
2025-12-31-$20.08M$0.00-$20.08M
2025-03-31-$21.72M
2024-12-31-$28.33M$0.00-$28.33M
2024-03-31-$14.87M$185,000.00-$15.05M
2023-12-31-$13.98M$73,000.00-$14.05M
2023-03-31-$18.37M
2022-12-31-$16.63M$25,000.00-$16.65M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$98.56M$397,000.00-$98.96M
2024-12-31-$81.15M$481,000.00-$81.63M
2023-12-31-$59.5M$115,000.00-$59.61M
2022-12-31-$54.56M$672,000.00-$55.23M